Trial Profile
A Randomized, Open-label, Two-arm Parallel Group, Comparative Study for Assessing the Clinical Benefit of Subcutaneous Injection of Plerixafor Plus G-CSF for Mobilization and Collection of Peripheral Hematopoietic Stem Cells in Japanese Patients With Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Plerixafor (Primary) ; Filgrastim
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Genzyme Corporation
- 03 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Jun 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 07 May 2015 Planned End Date changed from 1 May 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov record.